MBZUAI and GenBio AI have won the UAE AI Award 2025 in the AI Scientific Research category for their "Unified Protein Language Modeling Framework". The winning project enables AI to learn protein function, generate sequences, and predict 3D structures. The AI-driven simulation approach aims to accelerate drug development, reduce costs, and improve success rates. Why it matters: This award highlights the UAE's commitment to fostering AI innovation in biomedicine and drug discovery, positioning the region as a leader in AI-driven healthcare advancements.
Researchers at the Rosalind Franklin Institute are using generative AI, including GANs, to augment limited biological datasets, specifically mirtron data from mirtronDB. The synthetic data created mimics real-world samples, facilitating more comprehensive training of machine learning models, leading to improved mirtron identification tools. They also plan to apply Large Language Models (LLMs) to predict unknown patterns in sequence and structure biology problems. Why it matters: This research explores AI techniques to tackle data scarcity in biological research, potentially accelerating discoveries in noncoding RNA and transposable elements.
The AI4Bio Workshop at MBZUAI explored the intersection of AI and biology, focusing on AI-driven virtual organisms and foundation models. Eric Xing presented his vision of using AI to simulate biological activities, offering a safer alternative to physical experiments. Researchers like Le Song and Jen Philippe Vert are developing foundation models for biological systems, enhancing drug discovery and bioengineering. Why it matters: This signals the growing importance of AI in advancing biological research and healthcare innovation within the UAE and globally.
MBZUAI Professor Kun Zhang is working on applying AI to understand cause-and-effect relationships in biology, with the goal of accelerating scientific discovery and improving human health. He aims to develop foundation models for biology that can process diverse data types and provide insights into the causes and treatments of health problems. These models could help scientists develop new medicines and preventative measures for diseases. Why it matters: This research has the potential to significantly advance the field of medicine by enabling a deeper understanding of the complex biological processes that underlie disease.
MBZUAI has launched master’s and Ph.D. programs in computational biology, expanding its research into life sciences. This includes projects like AIDO (AI-Driven Digital Organism) and analysis of the Emirati Genome Program. The programs are part of MBZUAI’s School of Digital Public Health and aim to integrate computational biology with precision medicine. Why it matters: This initiative supports the UAE's vision for a knowledge-based economy and its ambition to become a global center for scientific and technological progress in biotechnology and healthcare.
Pierre Baldi from UC Irvine presented applications of AI to biomedicine, covering molecular-level analysis of circadian rhythms, real-time polyp detection in colonoscopy videos, and prediction of post-operative adverse outcomes. He discussed integrating AI in future AI-driven hospitals. The presentation was likely part of a panel discussion hosted by MBZUAI in collaboration with the Manara Center for Coexistence and Dialogue. Why it matters: This highlights the growing interest in AI applications within the healthcare sector in the UAE, particularly through institutions like MBZUAI.
A KAUST Rapid Research Response Team (R3T) is collaborating with healthcare stakeholders to combat COVID-19. Xin Gao and his Structural and Functional Bioinformatics (SFB) Group are developing an AI-based diagnosis pipeline from CT scans of COVID-19 patients. The AI pipeline aims to address the high false negative rates associated with nucleic acid detection. Why it matters: This research could improve COVID-19 diagnostics and potentially inform understanding of viral pathogenesis.
MBZUAI and BioMap have signed an MoU to establish the first biocomputing innovation research lab in the Middle East, located on MBZUAI's campus. The collaboration will focus on applying AI protein generation to life science models, addressing needs in drug design, energy, and environmental protection. The lab will research de novo design of oil degradation enzymes and identify drug targets for aging-associated and rare diseases. Why it matters: This partnership signals a growing focus on applying AI to critical life science challenges in the region, potentially leading to breakthroughs in drug discovery and sustainable energy solutions.